Placebo Matching Mitapivat + Mitapivat
Phase 3Active 0 views this week 0 watching💤 Quiet
Interest: 38/100
38
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Transfusion-dependent Alpha-Thalassemia
Conditions
Transfusion-dependent Alpha-Thalassemia, Transfusion-dependent Beta-Thalassemia
Trial Timeline
Nov 30, 2021 → Jun 1, 2029
NCT ID
NCT04770779About Placebo Matching Mitapivat + Mitapivat
Placebo Matching Mitapivat + Mitapivat is a phase 3 stage product being developed by Agios Pharmaceuticals for Transfusion-dependent Alpha-Thalassemia. The current trial status is active. This product is registered under clinical trial identifier NCT04770779. Target conditions include Transfusion-dependent Alpha-Thalassemia, Transfusion-dependent Beta-Thalassemia.
What happened to similar drugs?
1 of 3 similar drugs in Transfusion-dependent Alpha-Thalassemia were approved
Approved (1) Terminated (0) Active (2)
Hype Score Breakdown
Clinical
17
Activity
12
Company
9
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04770753 | Phase 3 | Active |
| NCT04770779 | Phase 3 | Active |
Competing Products
8 competing products in Transfusion-dependent Alpha-Thalassemia
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Deferasirox | Novartis | Phase 3 | 40 |
| Deferasirox dispersable tablet (DT) + Deferasirox film coated tablet (FCT) | Novartis | Phase 2 | 35 |
| Deferasirox + Deferoxamine (DFO) | Novartis | Phase 2 | 27 |
| Deferasirox granule formulation + Deferasirox DT formulation | Novartis | Phase 2 | 35 |
| Deferoxamine + Deferasirox | Novartis | Approved | 43 |
| Placebo Matching Mitapivat + Mitapivat | Agios Pharmaceuticals | Phase 3 | 38 |
| SLN124 + Placebo | Silence Therapeutics | Phase 1 | 19 |
| SLN124 is a GalNAc conjugated double stranded fully modified siRNA. Sodium chloride 0.9% w/v is used as Placebo | Silence Therapeutics | Phase 1 | 11 |